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Background: Epithelial ovarian cancer is one of the leading causes of gynaecological cancer morbidity and
mortality in women. Early stage ovarian cancer is usually asymptomatic, therefore, is often first diagnosed when it is
widely disseminated. Currently available diagnostics lack the requisite sensitivity and specificity to be implemented
as community-based screening tests. The identification of additional biomarkers may improve the diagnostic
efficiency of multivariate index assays. The aims of this study were to characterise and compare the ovarian tissue
immunohistochemical localisation and plasma concentrations of three putative ovarian cancer biomarkers: human
cationic antimicrobial protein-18 (hCAP-18); lactoferrin; and CD163 in normal healthy women and women with
ovarian cancer.
Methods: In this case–control cohort study, ovarian tissue and blood samples were obtained from 164 women
(73 controls, including 28 women with benign pelvic masses; 91 cancer, including 21 women with borderline tumours).
Localisation of each antigen within the ovary was assessed by immunohistochemistry and serum concentrations
determined by ELISA assays.
Results: Immunoreactive (ir) hCAP-18 and lactoferrin were identified in epithelial cells, while CD163 was predominately
localised in stromal cells. Tissue ir CD163 increased significantly (P<0.05) with disease grade. Median plasma
concentrations of soluble (s)CD163 were significantly greater in the cases (3220 ng/ml) than in controls (2488 ng/ml)
(P< 0.01). Median plasma concentrations of hCAP-18 and lactoferrin were not significantly different between cases and
controls. The classification efficiency of each biomarker (as determined by the area under the receiver operator
characteristic curve; AUC) was: 0.67± 0.04; 0.62 ± 0.08 and 0.51 ± 0.07 for sCD163, hCAP-18 and lactoferrin,
respectively. When the 3 biomarkers were modelled using stochastic gradient boosted logistic regression, the AUC
increased to 0.95 ± 0.03.
Conclusions: The data obtained in this study establishes the localisation and concentrations of CD163, hCAP-18,
and lactoferrin in ovarian tumours and peripheral blood. Individually, the 3 biomarkers display only modest
diagnostic efficiency as assessed by AUC. When combined in a multivariate index assay, however, diagnostic
efficiency increases significantly. As such, the utility of the biomarker panel, as an aid in the diagnosis of cancer in
symptomatic women, is worthy of further investigation in a larger phase 2 biomarker trial.
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Each year, more than 200,000 women are diagnosed with
ovarian cancer. Ovarian cancer is the sixth most common
cancer in women and the second most common type of
gynaecological cancer in the world [1]. In the USA, the
prevalence of ovarian cancer in postmenopausal women is
1 in 2,500 and the lifetime risk of a woman developing
ovarian cancer is 1 in 72. The age-adjusted incidence and
death rates for ovarian cancer are 12.7 and 8.2 per
100,000, respectively [2]. The average five-year survival
rate for ovarian cancer patients is approximately 46%. This
high overall mortality is a consequence of a failure to
detect this disease at an early stage. As there are no clinic-
ally overt early symptoms, most women (~75%) are first
diagnosed with disseminated disease (Stage III/IV) when
prognosis is poor. Despite recent progress in chemothera-
peutic treatments, the diagnosis of late stage disease is
associated with a five-year survival rate of ~20%. In
contrast, when ovarian cancer is identified at an early stage,
five year survival increases to ~80%. Unfortunately, there is
no cost effective screening test currently available [3].
Recent cohort studies [4,5] highlight the failure of the
currently available diagnostic tests to identify ovarian can-
cer early enough to affect disease progression and outcome.
Thus, the development of more accurate and earlier detec-
tion tests for ovarian cancer in pre-symptomatic women
are undoubtedly the number one priority for achieving
long-term reduction of mortality from ovarian cancer [3].
Human cationic antimicrobial protein of 18 kDa
(hCAP-18) is a major protein of the specific granules of
human neutrophils [6]. It is constitutively expressed in a
range of inflammatory and epithelial cells, particularly in
parts of the body exposed to the outside environment,
such as the airway, gut and urinary tract [7,8]; it is also
present in squamous epithelia [9] and in keratinocytes
during inflammatory skin diseases [10]. hCAP-18 is
over-expressed in ovarian cancer tumours and promotes
ovarian cancer cell proliferation [11]. Lactoferrin was
first recognised as a single-chain iron-binding protein
[12-14] and is highly expressed in milk and colostrum
[15,16]. Lactoferrin is also found in mucosal secretions
and in the specific granules of mature neutrophils [17-19].
Lactoferrin wields broad-spectrum antimicrobial activity
against pathogens such as bacteria, fungi, and viruses [17]
and is strongly up-regulated during inflammation [20].
It has been demonstrated that lactoferrin displays anti-
tumour activity by regulating tumorigenesis [21,22].
Lactoferrin gene polymorphisms have been described
in Chinese Han population and were significantly asso-
ciated with ovarian cancer [23]. CD163 is a haemoglobin
scavenger receptor solely expressed in the monocyte-
macrophage system and is a mediator against systemic
inflammation [24]. A soluble form is present in plasma
(sCD163) and has been used as a marker for monocyte/macrophage activity in diseases such as acute myeloid
leukaemia [25], rheumatoid arthritis [26,27] and tubercu-
losis [28]. A number of studies have found an association
between CD163 expression and ovarian cancer, notably in
the expression of tumour-associated macrophages [29-31].
There is a paucity of data on hCAP-18, lactoferrin and
CD163 and their expression in circulating plasma, and
in the tumours themselves, from women with ovarian
cancer, specifically with differing grades of disease. Thus, in
this study, an initial phase 1 biomarker trial (i.e. a proof-of-
principle, case–control study [32]) was conducted to
characterise disease-associated changes in: (i) antigen
expression in ovarian tissue (using immunohistochemistry);
and (ii) antigen concentration in plasma or serum
(determined by ELISA). The diagnostic efficiency of
each individual biomarker and in combination as a 3
biomarker panel to correctly identify women with ovarian
cancer was established (as assessed by the area under the
receiver operator characteristic curve, AUC).
Methods
Study design
The experimental design used to evaluate the diagnostic
efficiency of plasma concentrations of hCAP-18, lacto-
ferrin and CD163 was a retrospective case control study.
Written, informed consent was obtained from patients
involved in this study. A total of 164 patients were
included in the study. The control group included
women with no overt ovarian disease (n=45) and women
with benign masses (n= 28). The case cohort included
symptomatic women who were subsequently histologi-
cally diagnosed with ovarian cancer (n=70). Twenty-one
patients were diagnosed with borderline tumours. The
study was approved by the Royal Women’s Hospital,
Melbourne, Research and Human Ethics Committees
(Human Ethics Committee 02/29 and 02/30).
Blood collection
Whole blood (10 ml) was collected by peripheral
venipuncture for serum (blood collection tubes were
allowed to clot at room temperature for 30 min) or EDTA
tubes for plasma. Samples were centrifuged at 2,000 × g
for 10 min and the serum or plasma was collected.
Samples were stored at −80°C until analysed.
Tissue collection
To assess whether or not the expression of the three
biomarkers was altered in association with the presence of
ovarian cancer, where possible, matching ovarian tissue
samples were collected from patients. Control tissues were
collected from patients undergoing surgery as a result of
suspicious ultrasound images, palpable abdominal masses,
and from elective oopherectomy. Case tissues were
removed at the time of tumour cytoreduction surgery.
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by the method described by Silverberg [33]. As described
previously [34], tissues were snap frozen in liquid nitrogen
then stored at −80°C. Resected tissues not required for
clinical analysis were obtained from patients who presented
for surgery. Serum and plasma samples were collected from
patients after diagnosis and before surgery. Where possible,
blood and tissue collected from the same patient was used
for both IHC and ELISA analysis.
Immunohistochemistry (IHC)
The expression of hCAP-18, lactoferrin and CD163 in
ovarian tissues was also assessed using standard immu-
nohistochemical methodologies. hCAP-18 and lactofer-
rin immunohistochemical staining was performed using
paraffin-embedded tissues as previously described [35].
Rabbit hCAP-18 antibody [6] was used at a concentra-
tion of 0.5 mg/ml. A commercially-available lactoferrin
antibody (L-3262, Sigma Aldrich, MO, USA) was used at
20 μg/ml. CD163 staining was assessed using frozen
sections mounted on poly-l-lysine-coated slides. Frozen
tissue sections 5 μm thick were cut at −23°C using a
cryostat. Tissue sections were fixed in acetone for 15
min at −20°C then washed in TBS. Endogenous peroxid-
ase activity was blocked with 3% H2O2 in methanol for
10 minutes. Sections were incubated for 1 h in CD163
antibody (MAC 2–158, Abcam, UK) diluted to 4.5 μg/ml
in 1% BSA in TBS. Antibody binding was amplified
using biotin and streptavidin HRP for 10 minutes each
and the complex was visualised using DAB. Nuclei were
stained with Mayer’s haematoxylin. Mouse serum was
substituted for the antibody as a negative control.
Additional antibody staining was performed for the
CD163 study; macrophages (CD68, diluted to 0.8 μg/
ml), endothelial cells (CD31, diluted to 25 μg/ml) and
epithelial cells (EMA, diluted to 2 μg/ml) were tested on
2 cases and compared to the CD163 positive stain.
For all IHC analysis except CD163, sections were
assessed microscopically for positive DAB staining. The
staining was scored blind for the extent of staining. The
entire tissue section was scored and the extent of
staining was determined on a scale of 0–5 according to
the estimated percentage of cells stained: 0, ≤10%; 1, 11–
25%; 2, 26–50%; 3, 51–75%;4, 76–90%; 5, ≥90% [36]. For
CD163, staining did not seem to be epithelial in nature,
so Leica QWin Version 3 Image Analysis Software (Leica
Microsystems Imaging Solutions Ltd, Cambridge, UK)
was used to quantify tissue staining. Ten random fields of
view (FOV) were selected for each slide and for each FOV,
a ratio of CD163 stain/whole tissue was determined.
Enzyme Linked Immunosorbent Assay (ELISA)
Serum and plasma samples were assessed by ELISA as
previously described for hCAP-18 [6] and lactoferrin[37]. Serum and plasma samples were assayed for soluble
CD163, as described previously [38].
Statistical analyses
Assessing the association between plasma analyte
concentrations and disease grade
Multiple group comparisons were assessed by Kruskal-
Wallis tests. Dunn’s multiple comparison tests were used
for post-hoc two sample comparisons (GraphPad Prism
version 5.04 for Windows, GraphPad Software, San Diego,
CA, USA). A P value of < 0.05 was ascribed as statistically
significant. Data are presented as median value and inter-
quartile range.
Assessing the association between plasma analyte
concentrations in non-malignant and malignant cohorts
Data were partitioned into non-malignant (control = control
& benign) and malignant (case = borderline & grade 1–3)
groups. Two-sample group comparisons of median values
were assessed by Mann Whitney tests (GraphPad Prism).
Correlation between two sample groups was assessed by
Spearman’s rank correlations using the Bonferroni correc-
tion. Data are presented as median value and interquartile
range. Statistical significance was assigned at P < 0.05.
Receiver Operator Characteristic (ROC) curves
Receiver operator characteristic (ROC) curves were used
to determine if plasma concentrations of hCAP-18,
lactoferrin and sCD163 are of utility in identifying
women with ovarian cancer. In addition, the area under
the curve (AUC) was used to represent an overall summary
of diagnostic performance. A larger AUC indicates better
predictability of disease with a value of 1 representing
perfect predictive ability. Data were grouped as case
(grade 1–3) and control (control and benign) and assessed
by ROC analysis using commercially-available software
(GraphPad Prism). The AUC was calculated using the
Wilcoxon statistic [39]. The diagnostic performance of the
individual biomarkers was assessed by comparison of the
area under ROC curves using the method of Hanley and
McNeil [40] for ROC’s derived from the same cases.
Multivariate modelling
Multivariate classification models were developed, based
upon observed analyte plasma concentrations using a
stochastic gradient boosting model with a logistic loss
function as previously described [41] using the WEKA
software package [42]. The boosted logistic regression
algorithm reported a predicted posterior probability value
(i.e. the likelihood that a sample came from a woman with
ovarian cancer) for each patient sample. Predicted posterior
probability values (ppv) were then used to generate ROC
curves for each individual analyte and combined in a
3-biomarker panel.
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Patient characteristics
For the immunohistochemistry studies, a total number
of 94 tissue samples were assessed. The mean age of
women involved was 57 years, the youngest being 16
years and the oldest 85. For the ELISA assays, a total
number of 164 samples were assessed, with the mean
age of women being 57 years. Data were divided into
histological groups: controls and benign, borderline,
grade 1, grade 2 and grade 3 ovarian tumours. Each
group of ovarian cancer tissues contained a number of
tumour subtypes; mucinous, serous, endometrioid, tran-
sitional cell, clear cell, Brenner, or a mixture of two or
three subtypes.
Localisation of hCAP-18, lactoferrin and CD163 in ovarian
tissues
hCAP-18
Immunohistochemical localisation of hCAP-18 in
epithelial ovarian tumours is demonstrated in Figure 1,
for each histological grade. Immunoreactive hCAP-18
was not expressed in normal (n=6, Figure 1a) or benign
tissues (n=6, Figure 1b). Some staining was evident in
borderline tissues (n=6, average score = 1). Figure 1c
shows white cell staining (excluded from the IHC score)
in an hCAP-18-negative borderline tissue. Epithelial
staining appeared in 4 of the 5 grade 1 tissues (average
score = 1.6, Figure 1d). In grade 2 tissues (Figure 1e), 3 of
the 6 cases showed epithelial staining (average score = 1).
One of six grade 3 tissues (Figure 1f) stained for hCAP-18
(average score = 1). The IHC data of extent of staining for
hCAP-18 are represented in Table 1. Only grade 1 tissues
were significantly higher than normal tissues (P < 0.05).
An isotype antibody used as a negative control showed no
hCAP-18 staining in normal (Figure 1g) or tumour tissues
(Figure 1h).
Lactoferrin
Immunohistochemical expression of lactoferrin in epithelial
ovarian tumours is described in Figure 2, which shows
a representative image from each histological grade.
Figure 2a shows a normal tissue negative for lactoferrin,
however two of the 6 cases showed some epithelial staining
(extent score = 1). There was no lactoferrin staining in
benign tissues (n=6, Figure 2b). Of the borderline tissues
(Figure 2c), three of the four cases showed epithelial
staining (average score = 1.3). Grade 1 tissues showed the
most amount of epithelial staining (n=5, Figure 2d) where
all cases showed stain (average score = 2.4). Three grade 2
tissues (Figure 2e) had a score of 1 and one tissue showed
no lactoferrin staining. Of the grade 3 tissues, one case had
a score of 4 however the remaining 4 cases had a score of 1
or 0, depicted in Figure 2f. An isotype antibody used as a
negative control showed no lactoferrin staining in normal(Figure 2g) or tumour tissues (Figure 2h). The immu-
nohistochemical data is represented in Table 1; grade 1
tissues had significantly more lactoferrin stain than
control tissues.
CD163
A total of 63 frozen tissue samples were used to determine
the immunohistochemical expression of CD163 in epithe-
lial ovarian tumours. A representative image from each
histological grade is shown in Figure 3a-f. The black
arrows show that CD163 staining was confined to the
stroma of tissues; no stain was apparent in epithelial cells
(red arrows). An isotype antibody used as a negative
control showed no CD163 staining in normal (Figure 3g)
or tumour tissues (Figure 3h). Using the Leica QWin
software, staining was quantitated by creating a ratio of
the amount of immunological stain compared to the entire
tissue. CD163 staining was evident in all groups of tissues.
Grades 1 (n=11), 2 (n=12) and 3 (n=12) ovarian cancers
had a significantly higher ratio of stain than normal (n=5)
and benign (n=11) tissues (Figure 3i). The amount of
CD163 stain increased with tumour grade; staining was
found in tumour cells but not of epithelial origin. While
the data is not shown, additional antibodies were tested
by IHC for endothelial cells (CD31), macrophages
(CD68) and epithelial membrane (EMA). Compared to
the corresponding CD163 slide, the three antibodies did
not match in staining.
Concentration of hCAP-18, lactoferrin and sCD163 in
peripheral blood
hCAP-18
Concentrations of hCAP-18 in peripheral blood were
measured by ELISA (Figure 4). When data is stratified
by histological grade, both benign (n=8) and borderline
(n=8) samples were significantly higher than control
samples (n=18). Benign samples were 3.9-fold higher,
and borderline samples were 5.5-fold higher. No significant
differences were found between control samples and
tumour samples (n=37) when classified by both grade
and stage. When data was stratified by malignancy, i.e.
non-malignant (control and benign) and malignant
(borderline and all graded tumours), there was no signifi-
cant difference between groups.
Lactoferrin
Concentrations of lactoferrin in peripheral blood were
measured by ELISA (Figure 4). While benign samples
(n=8) were 1.5-fold higher than control (n=18), and
borderline (n=8) samples were 1.9-fold higher than
control, these results were not statistically significant.
No differences were detected between the median values
of control samples and any of the cancer groups (n=37),
nor when data was stratified by malignancy.
Table 1 Immunohistochemical data of hCAP-18 and lactoferrin in ovarian cancer tissues
Analyte Control Benign Borderline Grade 1 Grade 2 Grade 3
hCAP-18 0.0 ± 0.0 n=6 0.0 ± 0.0 n=6 0.2 ± 0.2 n=6 1.6 ± 0.5 * n=5 1.0 ± 0.5 n=6 0.2 ± 0.2 n=6
lactoferrin 0.3 ± 0.2 n=6 0.0 ± 0.0 n=6 1.3 ± 0.6 n=4 2.4 ± 0.6 * n=5 0.8 ± 0.3 n=4 1.2 ± 0.7 n=5
Immunohistochemical data is presented as mean extent score ± SEM. Statistically significant results compared with control samples are denoted with * (Student’s
t-test, P<0.05).
Figure 1 Immunohistochemical expression of hCAP-18 in ovarian tissues. Paraffin sections were stained by the immunoperoxidase method
as described in Materials and Methods. Representative fields were photographed at 200 X magnification. (a) Normal ovarian tissue; (b) benign
ovarian tissue; (c) borderline ovarian cancer tissue; (d) grade 1 ovarian tumour; (e) grade 2 ovarian tumour; (f) grade 3 ovarian tumour. Black
arrows denote brown epithelial hCAP-18 staining. Red arrow denotes white cell staining, excluded from extent scores. Negative controls from (g)
normal and (h) grade 1 tumour.
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Figure 2 Immunohistochemical expression of lactoferrin in ovarian tissues. Paraffin sections were stained by the immunoperoxidase
method as described in Materials and Methods section. Representative fields were photographed at 200 X magnification. (a) Normal ovarian
tissue; (b) benign ovarian tissue; (c) borderline ovarian cancer tissue; (d) grade 1 ovarian tumour; (e) grade 2 ovarian tumour; (f) grade 3 ovarian
tumour. Black arrows denote brown epithelial lactoferrin staining. Negative controls from (g) normal and (h) grade 1 tumour.
Lim et al. Journal of Ovarian Research 2013, 6:5 Page 6 of 11
http://www.ovarianresearch.com/content/6/1/5sCD163
Concentrations of sCD163 in peripheral blood were
measured by ELISA (Figure 4c). Data was stratified by
histological grade; benign (n=28), borderline (n=21),
grade 1 (n=8), grade 2 (n=15) and grade 3 (n=47). No
statistical differences were detected between the medians
of control samples (n=45) and any of the cancer groups(by grade and stage), nor when data was stratified by
malignancy, due to significance in the variance.
ROC curve analysis
ROC curves were generated for each analyte to deter-
mine their ability to detect ovarian cancer. Each analyte
was grouped into control (control and benign) and case
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Immunohistochemical expression of CD163 in ovarian tissues. Frozen sections were stained by the immunoperoxidase method as
described in Materials and Methods. Representative fields were photographed at 200 X magnification. (a) Normal ovarian tissue; (b) benign
ovarian tissue; (c) borderline ovarian cancer tissue; (d) grade 1 ovarian tumour; (e) grade 2 ovarian tumour; (f) grade 3 ovarian tumour. Black
arrows denote brown CD163 staining in non-epithelial cells. Red arrows indicate unstained epithelial cells. Negative controls from (g) normal and
(h) grade 1 tumour. (i) Tissue staining was quantified using Leica QWin Image Analysis Software, determining ratio of stain/whole tissue.
Statistically significant results compared with control samples are denoted with * (Mann–Whitney test, P<0.05).
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performed by ROC analysis using commercially-available
software. Individually, out of the three biomarkers,
sCD163 showed an ability to discriminate between control
and ovarian cancer cases, based on raw data (Table 2).
When subjected to boosted logistic regression, the posterior
probability values (ppv) generated for each biomarker
showed improved classification performance, as assessed by
increased AUC (Table 2 and Figure 5).
Discussion
The aim of this study was to establish the immunohisto-
chemical localisation of 3 putative biomarkers of ovarian
cancer and evaluate their utility as aids in the diagnosis
of ovarian cancer in symptomatic women.
The data obtained identify cancer-associated changes
in the immunohistochemical expression of all 3 anti-
gens within the ovary. Immunoreactive hCAP-18 and
ir lactoferrin was localised to ovarian epithelial cellsFigure 4 ELISA analysis of biomarker concentrations in peripheral
blood obtained from control and case (ovarian cancer) patients.
Plasma concentrations of lactoferrin (log10 ng/ml, blue circle); hCAP-18
(log ng/ml, orange square), sCD163 (log μg/ml, green diamond) are
presented as scatter plots with median bar. Data are stratified by case
and control.and its expression was greater in cases compared to
controls. The expression of ir CD163 was confined to
stromal cells but was similarly increased in tissues
obtained from women with ovarian cancer. The ir ex-
pression of all 3 biomarkers was significantly increased
in grade 1 ovarian cancer tissues. These data are
consistent with the hypothesis that these mediators
may participate in cell transformation and development of
metastatic potential.
Individually, the plasma concentrations of the biomarkers
displayed only modest diagnostic efficiency (as indicated by
AUC of less than 0.7). In combination as a 3-biomarker
panel (multivariate index assay, MIA), however, AUC
increased to 0.95 and, as such, may be of utility as an aid in
the diagnosis of ovarian cancer in symptomatic women.
While this phase 1 biomarker trial provides an estimate of
diagnostic efficiency based on AUC, a larger phase 2
biomarker trial would be required to provide robust
estimates of the sensitivity and specificity of the MIA.
Previously, hCAP-18 has been described in breast can-
cer [43], where hCAP-18 was constitutively expressed in
normal mammary gland epithelium and significantly
increased in high-grade tumours. While there was some
variance of hCAP-18 expression within groups, the study
concluded that there was a potential correlation between
degree of malignancy of breast cancer and hCAP-18
expression. This association was further explored [44],
finding that treatment with hCAP-18/LL-37 altered the
growth phenotype of breast cancer cells and stimulated
migration. Together with a lung cancer study [45] that
also found over-expression of hCAP-18/LL-37 increased
tumour growth, it is concluded that hCAP-18 contri-
butes to cancer metastasis.
Differential expression of hCAP-18 has also been
reported in ovarian cancer [11], where it was over-
expressed in ovarian cancer tumours when compared toTable 2 Comparison of the AUC of ROC curves for
individual and combined analytes
Analyte AUC (raw data) AUC (modelled data)
CD163 0.67 ± 0.04 * 0.79 ± 0.04 *
hCAP18 0.62 ± 0.08 0.89 ± 0.04 *
Lactoferrin 0.51 ± 0.07 0.80 ± 0.06 *
3-biomarker panel - 0.95 ± 0.03 *
Statistically significant results compared with control samples are denoted
with * (Student’s t-test, P<0.0005).
Figure 5 ROC curve analysis of 3-bimarker model. Receiver operating characteristic curve based on predicted posterior probability values
derived from boosted logistic regression modelling of CD163, hCAP18 and lactoferrin. AUC = 0.949 ± 0.027 (SE).
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breast and lung cancer studies, where high-grade
tumours express elevated levels of hCAP-18 when
compared to controls. Our study, however, shows that
normal ovarian tissue does not express hCAP-18 and
the highest amount of staining was in grade 1 tumour,
not grade 3. The concentration of hCAP-18 in blood
was significantly increased in benign and borderline
samples when compared to controls and graded tumours.
This dissimilarity may be due to a number of factors; very
limited sample numbers, or there could be a difference in
the expression of soluble hCAP-18 in the blood and
expression in tissues. There are, however, no studies that
measure circulating hCAP-18 concentrations in the blood
of cancer patients to verify this difference. Besides the
recent studies of its role in cancer metastasis, hCAP-18
has been mostly been linked with wound healing and
inflammatory disorders [10,46,47]. The results found in
this study indicate the need for further studies using a
larger cohort of blood samples.
CD163 has been identified, previously, in non-neoplastic
monocytes/macrophages and neoplasms of monocyte/
histiocyte derivation [48]. CD163 is strongly expressed in
“tumour-associated macrophages” and in a number of
cancer types its expression is associated with survival
[49,50], reflecting the tumour supportive nature of tumour-
associated macrophages [51]. Monocytes express CD163
constitutively at low levels, and expression increases
during macrophage differentiation [52] and infiltration
[53]. Increased sCD163 concentrations in plasma have
been reported in pathological conditions, including sepsis
and liver disease [54]. There, however, is no clinical or
biochemical evidence for inflammatory co-morbidity thatexplains the increase in sCD163 concentrations in these
patients. It, therefore, is possible that the increased
sCD163 is directly related to tumour-associated macro-
phages and other bone marrow-derived cells involved in
e.g. tumour angiogenesis [51].
The present study involves analysis of three biomarkers
in women with ovarian cancer, ranging from normal and
benign to all grades of disease. While analysis of each
group separates this study from others in the literature,
the small sample sizes is a limitation and also the crux of
the problem, as ovarian cancer is rarely caught in its early
stages. Further, the biomarkers should be compared to
CA-125, the gold standard in detecting advanced ovarian
cancer; however, CA-125 was not measured in the control
group (including benign and borderline samples) and
analysis cannot be performed. While age did not affect the
results in this study (data not shown), of note is whether
patient history of inflammatory diseases and tumour
subtype affected the expression of each biomarker. These
cannot be addressed for this study (inability to access
patient history after project conclusion and very small
sample size), but future studies building tissue banks would
benefit from obtaining these data sets for their samples.
Concluding comments
The data obtained in the study define ovarian cancer-
associated changes in the immunohistochemical expression
and plasma concentrations of three putative biomarkers.
When the biomarkers are combined as a multivariate
index assay, a diagnostic efficiency was achieved that is
commensurate with utility as an aid in the diagnosis of
ovarian cancer in symptomatic women. Interpretation and
application of the data obtained in this study must include
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trol design; and small cohort size. A phase 2 biomarker trial
would be required to address these caveats and provide
robust estimates to the sensitivity and specificity of the
multi-marker panel.
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